24
Participants
Start Date
December 31, 2004
Primary Completion Date
May 31, 2010
Study Completion Date
April 30, 2014
Bortezomib
Administered IV at the dose of 1.3 mg/m\^2 on a twice-weekly schedule for 2 consecutive weeks on days 1, 4, 8, and 11, followed by a 10 day rest period on days 12-21 (one cycle). In the absence of clinical progression, treatment continued for a minimum of 4 treatment cycles (or 12 weeks).
Lombardi Comprehensive Cancer Center at Georgetown University, Washington D.C.
Emory University, Atlanta
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus
Cleveland Clinic Foundation, Cleveland
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
M D Anderson Cancer Center, Houston
University of Colorado at Denver Health Sciences Center, Aurora
Massachusetts General Hospital Cancer Center, Boston
Dana-Farber Harvard Cancer Center, Boston
National Cancer Institute (NCI)
NIH